Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment
PRNewsWire
·
2026-07-09
·
via The Tech Buzz - Press Releases
Analyses across Kisunla (donanemab-azbt) trials providing further insights into the benefit-risk profile from…
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。